Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

106.16 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
58 59 Next >
Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript
GILD earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth?
Gilead missed earnings expectations Thursday, though reported strong sales growth for cancer drugs. 
Via Investor's Business Daily
Gilead Sciences Announces Second Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost. 
Via Benzinga
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Expert Ratings for Gilead Sciences
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now. 
Via InvestorPlace
3 Stocks Retirees Should Absolutely Love
These stocks offer solid income plus more. 
Via The Motley Fool
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
Exposures Death
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Price Over Earnings Overview: Gilead Sciences
Via Benzinga
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
From Gilead Sciences, Inc.
Via Business Wire
Trial Setback For Gilead Sciences: Shuts Late-Stage Magrolimab/Azacitidine Combo Study In Type Of Blood Cancer
Gilead Sciences Inc (NASDAQ: GILD) decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility  
Via Benzinga
Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed slightly higher on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
From Gilead Sciences, Inc.
Via Business Wire
Governor DeSantis Says He Would Sue the Drug Company Gilead for Trying to Save Lives
DeSantis made it clear that he thinks companies should only maximize profit and be subject to shareholder lawsuits if they do anything other than maximizing profits. So how does this get us to suing... 
Via Talk Markets
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
From Gilead Sciences, Inc.
Via Business Wire
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
From The Center for Disease Analysis Foundation
Via Business Wire
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
From Gilead Sciences, Inc.
Via Business Wire
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
From CDA Foundation
Via GlobeNewswire
2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street
The investment bank analysts who follow these stocks think they could deliver enormous gains in the not-so-distant future. 
Via The Motley Fool
The 7 Most Undervalued Nasdaq Stocks to Buy Now: July 2023
The market is soaring, but there is still time to buy these seven undervalued Nasdaq stocks before they head higher. 
Via InvestorPlace
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Death
Exposures COVID-19 Death
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
From Gilead Sciences, Inc.
Via Business Wire
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
It helps to offer products everyone needs. 
Via The Motley Fool
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
Read the latest report on NanoViricides here. 
Via Benzinga
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
These stocks are built to withstand a bear market. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback